Recognition and management of Parkinson’s disease during the premotor (prodromal) phase

References

• Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol. Aging24(2), 197–211 (2003).
   PubMed Web of Science ®Google Scholar
• Hawkes CH. The prodromal phase of sporadic Parkinson’s disease: does it exist and if so how long is it? Mov. Disord.23(13), 1799–1807 (2008).
   PubMedGoogle Scholar
• Koller WC. When does Parkinson’s disease begin? Neurology, 42(4 Suppl. 4), 27–31; discussion 41–48 (1992).
   PubMed Web of Science ®Google Scholar
• Wolters E. Variability in the clinical expression of Parkinson’s disease. J. Neurol. Sci.266(1–2), 197–203 (2008).
   PubMedGoogle Scholar
• Doty RL, Deems DA, Reynolds C, Stellar S. The olfactory and cognitive deficits of Parkinson’s disease: evidence for independence. Ann. Neurol.25, 166–171 (1989).
   PubMedGoogle Scholar
• Hawkes CH, Shephard BC, Daniel SE. Olfactory dysfunction in Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry62(5), 436–446 (1997).
   PubMed Web of Science ®Google Scholar
• Hawkes CH, Shephard BC, Daniel SE. Is Parkinson’s disease a primary olfactory disorder? QJM92(8), 473–480 (1999).
   PubMed Web of Science ®Google Scholar
• Goetz CG, Lutge W, Tanner CM. Autonomic dysfunction in Parkinson’s disease. Neurology36(1), 73–75 (1986).
   PubMed Web of Science ®Google Scholar
• Abbott RD, Petrovitch H, White LR et al. Frequency of bowel movements and the future risk of Parkinson’s disease. Neurology57(3), 456–462 (2001).
   PubMed Web of Science ®Google Scholar
• Ashraf W, Pfeiffer RF, Park F, Lof J, Quigley EM. Constipation in Parkinson’s disease: objective assessment and response to psyllium. Mov. Disord.12(6), 946–951 (1997).
   PubMed Web of Science ®Google Scholar
• Awerbuch GI, Sandyk R. Autonomic functions in the early stages of Parkinson’s disease. Int. J. Neurosci.74(1–4), 9–16 (1994).
   PubMedGoogle Scholar
• Chaudhuri KR, Healy DG, Schapira AH. Non-motor symptoms of Parkinson’s disease: diagnosis and management. Lancet Neurol.5(3), 235–245 (2006).
   PubMed Web of Science ®Google Scholar
• Magerkurth C, Schnitzer R, Braune S. Symptoms of autonomic failure in Parkinson’s disease: prevalence and impact on daily life. Clin. Auton. Res.15(2), 76–82 (2005).
   PubMed Web of Science ®Google Scholar
• Edwards L, Quigley EM, Hofman R, Pfeiffer RF. Gastrointestinal symptoms in Parkinson disease: 18-month follow-up study. Mov. Disord.8(1), 83–86 (1993).
   PubMed Web of Science ®Google Scholar
• Kaye J, Gage H, Kimber A, Storey L, Trend P. Excess burden of constipation in Parkinson’s disease: a pilot study. Mov. Disord.21(8), 1270–1273 (2006).
   PubMed Web of Science ®Google Scholar
• Ueki A, Otsuka M. Life style risks of Parkinson’s disease: association between decreased water intake and constipation. J. Neurol.251(Suppl. 7), vII18–vII23 (2004).
   PubMedGoogle Scholar
• Braak H, de Vos RA, Bohl J, Del Tredici K. Gastric α-synuclein immunoreactive inclusions in Meissner’s and Auerbach’s plexuses in cases staged for Parkinson’s disease-related brain pathology. Neurosci. Lett.396(1), 67–72 (2006).
   PubMed Web of Science ®Google Scholar
• Oyanagi K, Wakabayashi K, Ohama E et al. Lewy bodies in the lower sacral parasympathetic neurons of a patient with Parkinson’s disease. Acta Neuropathol.80(5), 558–559 (1990).
   PubMed Web of Science ®Google Scholar
• Kupsky WJ, Grimes MM, Sweeting J, Bertsch R, Cote LJ. Parkinson’s disease and megacolon: concentric hyaline inclusions (Lewy bodies) in enteric ganglion cells. Neurology37(7), 1253–1255 (1987).
   PubMed Web of Science ®Google Scholar
• Rosenthal MJ, Marshall CE. Sigmoid volvulus in association with parkinsonism. Report of four cases. J. Am. Geriatr. Soc.35(7), 683–684 (1987).
   PubMedGoogle Scholar
• Hu G, Jousilahti P, Nissinen A et al. Body mass index and the risk of Parkinson disease. Neurology67(11), 1955–1999 (2006).
   PubMed Web of Science ®Google Scholar
• Ragonese P, D’Aelio M, Callari G et al. Body mass index does not change before Parkinson’s disease onset. Eur. J. Neurol.15(9), 965–968 (2008).
   PubMed Web of Science ®Google Scholar
• Driver JA, Kurth T, Buring JE et al. Parkinson disease and risk of mortality. A prospective comorbidity-matched cohort study. Neurology70(16 Pt 2), 1423–1430 (2008).
   PubMed Web of Science ®Google Scholar
• Hernan MA, Takkouche B, Caamano-Isorna F, Gestal-OteroJJ. A meta-anaysis of coffee drinking, cigarette smoking, and the risk of Parkinson’s disease. Ann. Neurol.52, 276–284 (2002).
   PubMed Web of Science ®Google Scholar
• Goldstein DS. Dysautonomia in Parkinson’s disease: neurocardiological abnormalities. Lancet Neurol.2(11), 669–676 (2003).
   PubMed Web of Science ®Google Scholar
• Goldstein DS. Orthostatic hypotension as an early finding in Parkinson’s disease. Clin. Auton. Res.16(1), 46–54 (2006).
   PubMed Web of Science ®Google Scholar
• Fowler CJ. Urinary disorders in Parkinson’s disease and multiple system atrophy. Funct. Neurol.16(3), 277–282 (2001).
   PubMed Web of Science ®Google Scholar
• Kaufmann H, Nahm K, Purohit D, Wolfe D. Autonomic failure as the initial presentation of Parkinson disease and dementia with Lewy bodies. Neurology63(6), 1093–1095 (2004).
   PubMed Web of Science ®Google Scholar
• Sakakibara R, Uchiyama T, Yamanishi T, Shirai K, Hattori T. Bladder and bowel dysfunction in Parkinson’s disease. J. Neural Transm.115(3), 443–460 (2008).
   PubMed Web of Science ®Google Scholar
• Okun MS, McDonald WM, DeLong MR. Refractory nonmotor symptoms in male patients with Parkinson disease due to testosterone deficiency: a common unrecognized comorbidity. Arch. Neurol.59(5), 807–811 (2002).
   PubMedGoogle Scholar
• Gao X, Chen H, Schwarzschild MA et al. Erectile function and risk of Parkinson’s disease. Am. J. Epidemiol.166(12), 1446–1450 (2007).
   PubMed Web of Science ®Google Scholar
• Borek LL, Kohn R, Friedman JH. Mood and sleep in Parkinson’s disease. J. Clin. Psychiatry67(6), 958–963 (2006).
   PubMed Web of Science ®Google Scholar
• Boeve BF, Silber MH, Ferman TJ, Lucas JA, Parisi JE. Association of REM sleep behavior disorder and neurodegenerative disease may reflect an underlying synucleinopathy. Mov. Disord.16(4), 622–630 (2001).
   PubMed Web of Science ®Google Scholar
• Iranzo A, Santamaría J, Rye DB et al. Characteristics of idiopathic REM sleep behavior disorder and that associated with MSA and PD. Neurology65(2), 247–252 (2005).
   PubMed Web of Science ®Google Scholar
• Olson EJ, Boeve BF, and Silber MH. Rapid eye movement sleep behaviour disorder: demographic, clinical and laboratory findings in 93 cases. Brain123(Pt 2), 331–339 (2000).
   PubMed Web of Science ®Google Scholar
• Postuma RB, Gagnon JF, Vendette M, Fantini ML, Massicotte-Marquez J, Montplaisir J. Quantifying the risk of neurodegenerative disease in idiopathic REM sleep behavior disorder. Neurology72, 1296–1300 (2009).
   PubMed Web of Science ®Google Scholar
• Hilker R, Burghaus L, Razai N, Jacobs AH, Szelies B, Heiss WD. Functional brain imaging in combined motor and sleep disorders. J. Neurol. Sci.248(1–2), 223–226 (2006).
   PubMed Web of Science ®Google Scholar
• Schenck CH, Bundlie SR, Mahowald MW. Delayed emergence of a parkinsonian disorder in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behaviour disorder. Neurology46(2), 388–393 (1996).
   PubMed Web of Science ®Google Scholar
• Albin RL, Koeppe RA, Chervin RD et al. Decreased striatal dopaminergic innervation in REM sleep behavior disorder. Neurology55(9), 1410–1412 (2000).
   PubMed Web of Science ®Google Scholar
• Eisensehr I, Linke R, Noachtar S, Schwarz J, Gildehaus FJ, Tatsch K. Reduced striatal dopamine transporters in idiopathic rapid eye movement sleep behaviour disorder. Comparison with Parkinson’s disease and controls. Brain123(Pt 6), 1155–1160 (2000).
   PubMed Web of Science ®Google Scholar
• Uchiyama M, Isse K, Tanaka K et al. Incidental Lewy body disease in a patient with REM sleep behavior disorder. Neurology45(4), 709–712 (1995).
   PubMedGoogle Scholar
• Fabbrini G, Barbanti P, Aurilia C, Vanacore N, Pauletti C, Meco G. Excessive daytime sleepiness in de novo and treated Parkinson’s disease. Mov. Disord.17(5), 1026–1030 (2002).
   PubMed Web of Science ®Google Scholar
• Abbott RD, Ross GW, White LR et al. Excessive daytime sleepiness and subsequent development of Parkinson disease. Neurology65(9), 1442–1446 (2005).
   PubMed Web of Science ®Google Scholar
• Wolters E, Braak H. Parkinson’s disease: premotor clinico–pathological correlations. J. Neural Transm. Suppl.70, 309–319 (2006).
   Google Scholar
• Doty RL, Deems DA, Stellar S. Olfactory dysfunction in parkinsonism: a general deficit unrelated to neurologic signs, disease stage, or disease duration. Neurology38(8), 1237–1244 (1988).
   PubMed Web of Science ®Google Scholar
• Doty RL, Stern MB, Pfeiffer C, Gollomp SM, Hurtig HI. Bilateral olfactory dysfunction in early stage treated and untreated idiopathic Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry55(2), 138–142 (1992).
   PubMed Web of Science ®Google Scholar
• Tissingh G, Berendse HW, Bergmans P et al. Loss of olfaction in de novo and treated Parkinson’s disease: possible implications for early diagnosis. Mov. Disord.16(1), 41–46 (2001).
   PubMed Web of Science ®Google Scholar
• Siderowf A, Newberg A, Chou KL et al. [99mTc]TRODAT-1 SPECT imaging correlates with odor identification in early Parkinson disease. Neurology64(10), 1716–1720 (2005).
   PubMed Web of Science ®Google Scholar
• Henderson JM, Lu Y, Wang S, Cartwright H, Halliday GM. Olfactory deficits and sleep disturbances in Parkinson’s disease: a case–control survey. J. Neurol. Neurosurg. Psychiatry74(7), 956–958 (2003).
   PubMedGoogle Scholar
• Ross GW, Petrovitch H, Abbott RD et al. Association of olfactory dysfunction with risk for future Parkinson’s disease. Ann. Neurol.63(2), 167–173 (2008).
   PubMed Web of Science ®Google Scholar
• Ponsen MM, Stoffers D, Booij J, van Eck-Smit BL, Wolters ECh, Berendse HW. Idiopathic hyposmia as a preclinical sign of Parkinson’s disease. Ann. Neurol.56(2), 173–181 (2004).
   PubMed Web of Science ®Google Scholar
• Marras C, Goldman S, Smith A et al. Smell identification ability in twin pairs discordant for Parkinson’s disease. Mov. Disord.20(6), 687–693 (2005).
   PubMedGoogle Scholar
• Stamey W, Davidson A, Jankovic J. Shoulder pain: a presenting symptom of Parkinson disease. J. Clin. Rheumatol.14(4), 253–254 (2008).
   PubMedGoogle Scholar
• Braak H, Sastre M, Bohl JR, de Vos RA, Del Tredici K. Parkinson’s disease: lesions in dorsal horn layer I, involvement of parasympathetic and sympathetic pre- and postganglionic neurons. Acta Neuropathol.113(4), 421–429 (2007).
   PubMed Web of Science ®Google Scholar
• Reijnders JS, Ehrt U, Weber WE, Aarsland D, Leentjens AF. A systematic review of prevalence studies of depression in Parkinson’s disease. Mov. Disord.23(2), 183–189; quiz 313 (2008).
   PubMed Web of Science ®Google Scholar
• O ’Sullivan SS, Williams DR, Gallagher DA, Massey LA, Silveira-Moriyama L, Lees AJ. Nonmotor symptoms as presenting complaints in Parkinson’s disease: a clinicopathological study. Mov. Disord.23(1), 101–106 (2008).
   PubMedGoogle Scholar
• Wolters EC, Francot CM. Mental dysfunction in Parkinson’s disease. Parkinsonism Relat. Disord.4(3), 107–112 (1998).
   PubMedGoogle Scholar
• Bhattacharya K, Saadia D, Eisenkraft B et al. Brain magnetic resonance imaging in multiple-system atrophy and Parkinson disease: a diagnostic algorithm. Arch. Neurol.59(5), 835–842 (2002).
   PubMedGoogle Scholar
• Kraft E, Schwarz J, Trenkwalder C, Vogl T, Pfluger T, Oertel WH. The combination of hypointense and hyperintense signal changes on T2-weighted magnetic resonance imaging sequences: a specific marker of multiple system atrophy? Arch. Neurol.56(2), 225–228 (1999).
   PubMedGoogle Scholar
• Kraft E, Trenkwalder C, Auer DP. T2*-weighted MRI differentiates multiple system atrophy from Parkinson’s disease. Neurology59(8), 1265–1267 (2002).
   PubMedGoogle Scholar
• Schrag A, Good CD, Miszkiel K et al. Differentiation of atypical parkinsonian syndromes with routine MRI. Neurology54(3), 697–702 (2000).
   PubMed Web of Science ®Google Scholar
• Warmuth -Metz M, Naumann M, Csoti I, Solymosi L. Measurement of the midbrain diameter on routine magnetic resonance imaging: a simple and accurate method of differentiating between Parkinson disease and progressive supranuclear palsy. Arch. Neurol.58(7), 1076–1079 (2001).
   PubMedGoogle Scholar
• Yoshita M. Differentiation of idiopathic Parkinson’s disease from striatonigral degeneration and progressive supranuclear palsy using iodine-123 meta-iodobenzylguanidine myocardial scintigraphy. J. Neurol. Sci.155(1), 60–67 (1998).
   PubMed Web of Science ®Google Scholar
• Benamer HT, Oertel WH, Patterson J et al. Prospective study of presynaptic dopaminergic imaging in patients with mild parkinsonism and tremor disorders: part 1. Baseline and 3-month observations. Mov. Disord.18(9), 977–984 (2003).
   PubMedGoogle Scholar
• Marek KL, Seibyl JP, Zoghbi SS et al. [123I] β-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson’s disease. Neurology46(1), 231–237 (1996).
   PubMed Web of Science ®Google Scholar
• Wenning GK, Donnemiller E, Granata R, Riccabona G, Poewe W. 123I-β-CIT and 123I-IBZM-SPECT scanning in levodopa-naive Parkinson’s disease. Mov. Disord.13(3), 438–445 (1998).
   PubMedGoogle Scholar
• Winogrodzka A, Bergmans P, Booij J, van Royen EA, Janssen AG, Wolters EC. [123I]FP-CIT SPECT is a useful method to monitor the rate of dopaminergic degeneration in early-stage Parkinson’s disease. J. Neural Transm.108(8–9), 1011–1019 (2001).
   PubMed Web of Science ®Google Scholar
• Benamer TS, Patterson J, Grosset DG et al. Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [123I]-FP-CIT study group. Mov. Disord.15(3), 503–510 (2000).
   PubMed Web of Science ®Google Scholar
• Booij J, Speelman JD, Horstink MW, Wolters EC. The clinical benefit of imaging striatal dopamine transporters with [123I]FP-CIT SPET in differentiating patients with presynaptic parkinsonism from those with other forms of parkinsonism. Eur. J. Nucl. Med.28(3), 266–272 (2001).
   PubMedGoogle Scholar
• Gerschlager W, Bencsits G, Pirker W et al. [123I]β-CIT SPECT distinguishes vascular parkinsonism from Parkinson’s disease. Mov. Disord.17(3), 518–523 (2002).
   PubMedGoogle Scholar
• Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA287(13), 1653–1661 (2002).
   PubMed Web of Science ®Google Scholar
• Winogrodzka A, Booij J, Wolters E. Disease-related and drug-induced changes in dopamine transporter expression might undermine the reliability of imaging studies of disease progression in Parkinson’s disease. Parkinsonism Relat. Disord.11(8), 475–484 (2005).
   PubMed Web of Science ®Google Scholar
• Braune S, Reinhardt M, Schnitzer R, Riedel A, Lücking CH. Cardiac uptake of [123I]MIBG separates Parkinson’s disease from multiple system atrophy. Neurology53(5), 1020–1025 (1999).
   PubMed Web of Science ®Google Scholar
• Yoshita M, Hayashi M, Hirai S. Decreased myocardial accumulation of 123I-meta-iodobenzyl guanidine in Parkinson’s disease. Nucl. Med. Commun.19(2), 137–142 (1998).
   PubMedGoogle Scholar
• Becker G, Seufert J, Bogdahn U, Reichmann H, Reiners K. Degeneration of substantia nigra in chronic Parkinson’s disease visualized by transcranial color-coded real-time sonography. Neurology45(1), 182–184 (1995).
   PubMed Web of Science ®Google Scholar
• Berg D, Godau J, Walter U. Transcranial sonography in movement disorders. Lancet Neurol.7(11), 1044–1055 (2008).
   PubMed Web of Science ®Google Scholar
• Walter U, Dressler D, Wolters A, Probst T, Grossmann A, Benecke R. Sonographic discrimination of corticobasal degeneration vs progressive supranuclear palsy. Neurology63(3), 504–509 (2004).
   PubMed Web of Science ®Google Scholar
• Walter U, Dressler D, Wolters A, Wittstock M, Greim B, Benecke R. Sonographic discrimination of dementia with Lewy bodies and Parkinson’s disease with dementia. J. Neurol.253(4), 448–454 (2006).
   PubMed Web of Science ®Google Scholar
• Berg D, Merz B, Reiners K, Naumann M, Becker G. Five-year follow-up study of hyperechogenicity of the substantia nigra in Parkinson’s disease. Mov. Disord.20(3), 383–385 (2005).
   PubMed Web of Science ®Google Scholar
• Berg D, Siefker C, Becker G. Echogenicity of the substantia nigra in Parkinson’s disease and its relation to clinical findings. J. Neurol.248(8), 684–689 (2001).
   PubMed Web of Science ®Google Scholar
• Walter U, Behnke S, Eyding J et al. Transcranial brain parenchyma sonography in movement disorders: state of the art. Ultrasound Med. Biol.33(1), 15–25 (2007).
   PubMed Web of Science ®Google Scholar
• Walter U, Dressler D, Wolters A, Wittstock M, Benecke R. Transcranial brain sonography findings in clinical subgroups of idiopathic Parkinson’s disease. Mov. Disord.22(1), 48–54 (2007).
   PubMed Web of Science ®Google Scholar
• Behnke S, Berg D, Naumann M, Becker G. Differentiation of Parkinson’s disease and atypical parkinsonian syndromes by transcranial ultrasound. J. Neurol. Neurosurg. Psychiatry76(3), 423–425 (2005).
   PubMed Web of Science ®Google Scholar
• Gaenslen A, Unmuth B, Godau J et al. The specificity and sensitivity of transcranial ultrasound in the differential diagnosis of Parkinson’s disease: a prospective blinded study. Lancet Neurol.7(5), 417–424 (2008).
   PubMed Web of Science ®Google Scholar
• Klein C, Schlossmacher MG. The genetics of Parkinson disease: implications for neurological care. Nat. Clin. Pract. Neurol.2(3), 136–146 (2006).
   PubMedGoogle Scholar
• Le W, Chen S, Jankovic J. Etiopathogenesis of Parkinson disease: a new beginning? Neuroscientist15(1), 28–35 (2008).
   PubMedGoogle Scholar
• Siderowf A, Stern MB. Preclinical diagnosis of Parkinson’s disease: are we there yet? Curr. Neurol. Neurosci. Rep.6(4), 295–301 (2006).
   PubMed Web of Science ®Google Scholar
• Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico–pathological study of 100 cases. J. Neurol. Neurosurg. Psychiatry55(3), 181–184 (1992).
   PubMed Web of Science ®Google Scholar
• Soffer EE, Metcalf A, Launspach J. Misoprostol is effective treatment for patients with severe chronic constipation. Dig. Dis. Sci.39(5), 929–933 (1994).
   PubMed Web of Science ®Google Scholar
• Ney P, Pandita RK, Newgreen DT, Breidenbach A, Stöhr T, Andersson KE. Pharmacological characterization of a novel investigational antimuscarinic drug, fesoterodine, in vitro and in vivo.BJU Int.101(8), 1036–1042 (2008).
   PubMed Web of Science ®Google Scholar
• Schurch B, Schmid DM, Stohrer M. Treatment of neurogenic incontinence with botulinum toxin A. N. Engl. J. Med.342(9), 665 (2000).
   PubMed Web of Science ®Google Scholar
• Chancellor MB, Anderson RU, Boone TB. Pharmacotherapy for neurogenic detrusor overactivity. Am. J. Phys. Med. Rehabil.85(6), 536–545 (2006).
   PubMed Web of Science ®Google Scholar
• McVary KT Clinical practice. Erectile dysfunction. N. Engl. J. Med.357(24), 2472–2481 (2007).
   PubMed Web of Science ®Google Scholar
• Braak H, Ghebremedhin E, Rüb U, Bratzke H, Del Tredici K. Stages in the development of Parkinson’s disease-related pathology. Cell Tissue Res.318(1), 121–134 (2004).
   PubMed Web of Science ®Google Scholar
• Gagnon J, Postuma RB, Montplaisir J. Update on the pharmacology of REM sleep behavior disorder. Neurology67(5), 742–747 (2006).
   PubMedGoogle Scholar
• Miyasaki JM, Shannon K, Voon V et al. Practice parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology66(7), 996–1002 (2006).
   PubMed Web of Science ®Google Scholar
• Serrano-Duenas M. [A comparison between low doses of amitriptyline and low doses of fluoxetine used in the control of depression in patients suffering from Parkinson’s disease]. Rev. Neurol.35(11), 1010–1014 (2002).
   PubMed Web of Science ®Google Scholar
• Richard IH, Kurlan R. A survey of antidepressant drug use in Parkinson’s disease. Parkinson Study Group. Neurology49(4), 1168–1170 (1997).
   PubMed Web of Science ®Google Scholar
• Bejjani BP, Damier P, Arnulf I et al. Transient acute depression induced by high-frequency deep-brain stimulation. N. Engl. J. Med.340(19), 1476–1480 (1999).
   PubMed Web of Science ®Google Scholar
• Voon V, Kubu C, Krack P, Houeto JL, Tröster AI. Deep brain stimulation: neuropsychological and neuropsychiatric issues. Mov. Disord.21(Suppl. 14), S305–S327 (2006).
   PubMed Web of Science ®Google Scholar
• Cassano P, Lattanzi L, Soldani F et al. Pramipexole in treatment-resistant depression: an extended follow-up. Depress. Anxiety20(3), 131–138 (2004).
   PubMed Web of Science ®Google Scholar
• Schapira AH Neuroprotection and dopamine agonists. Neurology58(4 Suppl. 1), S9–S18 (2002).
   PubMedGoogle Scholar
• Ostow M. Pramipexole for depression. Am. J. Psychiatry159(2), 320–321 (2002).
   PubMedGoogle Scholar
• Zarate CA Jr, Payne JL, Singh J et al. Pramipexole for bipolar II depression: a placebo-controlled proof of concept study. Biol. Psychiatry56(1), 54–60 (2004).
   PubMed Web of Science ®Google Scholar
• Naoi M, Maruyama W, Youdim MB, Yu P, Boulton AA. Anti-apoptotic function of propargyloamine inhibitors of type-B monoamine oxidase. Inflammopharmacology11(2), 175–181 (2003).
   PubMedGoogle Scholar
• Takuma K, Baba A, Matsuda T. Astrocyte apoptosis: implications for neuroprotection. Prog. Neurobiol.72(2), 111–127 (2004).
   PubMed Web of Science ®Google Scholar
• Maruyama W, Akao Y, Carrillo MC et al. Neuroprotection by propargylamines in Parkinson’s disease: suppression of apoptosis and induction of prosurvival genes. Neurotoxicol. Teratol.24(5), 675–682 (2002).
   PubMed Web of Science ®Google Scholar
• Maruyama W, Takahashi T, Youdim M, Naoi M. The anti-Parkinson drug, rasagiline, prevents apoptotic DNA damage induced by peroxynitrite in human dopaminergic neuroblastoma SH-SY5Y cells. J. Neural Transm.109(4), 467–481 (2002).
   PubMed Web of Science ®Google Scholar
• Swanson CR, Sesso SL, Emborg ME. Can we prevent parkinson’s disease? Front. Biosci.14, 1642–1660 (2009).
   Google Scholar
• Poewe W. Treatments for Parkinson disease – past achievements and current clinical needs. Neurology72(7 Suppl.), S65–S73 (2009).
   PubMed Web of Science ®Google Scholar
• Rascol O. “Disease-modification” trials in Parkinson disease: target populations, endpoints, and study design. Neurology72(7 Suppl.), S51–S58 (2009).
   PubMed Web of Science ®Google Scholar
• Olanow CW, Kieburtz K, Schapira AH. Why have we failed to achieve neuroprotection in Parkinson’s disease? Ann. Neurol.64(Suppl. 2), S101–S110 (2008).
   PubMed Web of Science ®Google Scholar
• Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch. Neurol.61(4), 561–566 (2004).
   PubMedGoogle Scholar
• Rascol O, Olanow CW. ADAGIO: a prospective, double-blind, delayed-start study to examine the disease modifying effect of rasagiline in early Parkinson’s disease (PD). Eur. J. Neurol.15(Suppl. 3), 413 (2008).
   PubMedGoogle Scholar